A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Phentermine
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Jun 2017 Results (n=334) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Mar 2017 Results assessing effectiveness of Canagliflozin and Phentermine for weight management in overweight and obese individuals without diabetes published in the Diabetes Care.
    • 16 Sep 2016 Results (n=334) assessing efficacy and safety, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top